Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 239,118 shares, a decline of 74.5% from the June 30th total of 938,810 shares. Based on an average daily volume of 1,138,425 shares, the short-interest ratio is currently 0.2 days. Approximately 1.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Jupiter Neurosciences Stock Down 6.2%

NASDAQ JUNS traded down $0.01 during trading hours on Monday, reaching $0.11. The company’s stock had a trading volume of 2,674,890 shares, compared to its average volume of 20,359,588. Jupiter Neurosciences has a 1 year low of $0.11 and a 1 year high of $1.84. The firm’s 50-day moving average price is $0.22 and its 200-day moving average price is $0.42.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.23 million.

Institutional Trading of Jupiter Neurosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vestor Capital LLC lifted its stake in Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares in the last quarter. Yorkville Advisors Global LP purchased a new position in shares of Jupiter Neurosciences during the fourth quarter valued at about $135,000. Geode Capital Management LLC increased its holdings in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the last quarter. Finally, Allen Capital Group LLC bought a new stake in shares of Jupiter Neurosciences in the fourth quarter worth about $31,000.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.